Genetic Analysis of the Flagella Gene of Lyme Disease Spirochetes (Borrelia burgdorferi) Isolated from the Offshore Kinmen Island of Taiwan  by Chao, L.L. & Shih, C.M.
13th International Congress on Infectious Diseases Abstracts, Poster Presentations e231
40.065
Genetic Analysis of the Flagella Gene of Lyme Disease
Spirochetes (Borrelia burgdorferi) Isolated from the Off-
shore Kinmen Island of Taiwan
L.L. Chao ∗, C.M. Shih
Department of Parasitology and Tropical Medicine, National
Defense Medical Center, Taipei, Taiwan
The ﬂagella gene of Lyme disease spirochetes (Borre-
lia burgdorferi) was analyzed for the ﬁrst time in Taiwan.
The genetic identities of these Taiwan isolates (TWKM1-
7) were clariﬁed by comparing their sequence similarities
and nucleotide distance values of the PCR-ampliﬁed ﬂagella
genes with three major genospecies of Lyme disease spiro-
chetes for human infection and other zoonotic species of
Borrelia spirochetes. Results from 26 isolates indicate that
the sequence similarity of these Taiwan isolates revealed a
highly homogeneous genotype, ranging from 99.3% to 100%,
within the genospecies of B. burgdorferi sensu stricto and
was distinguished from other genospecies of Borrelia iso-
lates. Moreover, the nucleotide distance values performed
by a pairwise distance calculation (Kimura 2-parameter dis-
tance) revealed a highly homogeneity (<0.019) within the
same genospecies of these Taiwan isolates and a highly het-
erogeneity (>0.05) among other genospecies of spirochetes.
The phylogenetic analysis also demonstrated that all these
Taiwan isolates were closely related to the genospecies of B.
burgdorferi sensu stricto within the same phylogenic group
of B. burgdorferi sensu lato and can be clearly distinguished
from other zoonotic species of Borrelia isolates. Thus, we
conclude that all these Taiwan isolates should be classiﬁed
into the genospecies of B. burgdorferi sensu stricto based
on the genetic identity of the ﬂagella gene.
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Isolation, Identiﬁcation and Growth of Enterobacter
sakazakii in Powdered Infant Formula Milk
M. Ghassem, N. Abdullah Sani ∗, A.S. Babji
National University of Malaysia, Bangi, Malaysia
Background: Enterobacter sakazakii has been associated
with outbreaks of a rare form of infant meningitis, necrotiz-
ing entercolitis, bacteraemia andmay cause death. Although
the origin of the microorganism has not been established,
several cases have been associated with the consumption of
contaminated powdered infant formulae. The high mortality
rate (40—80%) and severity of infection in immunocompro-
mised infants, neonate of low birth weight and infants of
HIV-positive mothers plus the lack of information about this
organism led to this study of the prevalence of E. sakazakii in
infant formula milk (IFM) available in the Malaysian market
and some biological characterization of the organism.
Methods: Isolation and identiﬁcation of E. sakazakii
in IFM was conﬁrmed using a chromogenic media, rapid
biochemical tests API20E and Microgen as well as Real-
Time PCR. All presumptive E. sakazakii strains were also
conﬁrmed using 16S rDNA sequencing. The growth charac-
teristics of three isolated E. sakazakii strains and type strain
ATCC 51329 were evaluated at 4, 10, 25, 37, 45 and 50 ◦C.
Results: The incidence varied from 0-33.3% in 72 samples
evaluated from 6 different brands of IFM. E. sakazakii had
a doubling time of 3.64 h and 29.92min at 10 and 25 ◦C in
reconstitute IFM respectively.
Conclusion: The result of these study shows that E.
sakazakii is prevalent in dried IFM in the Malaysian market
and has a doubling time of 29.92min in IFM at room tem-
perature (25 ◦C). This is a cause of concern if IFM is being
prepared and kept at that temperature for more than half an
hour before feeding as it gives the opportunity for E. sakaza-
kii to multiply in numbers and causing infection to the high
risk group, i.e. infants and neonates.
doi:10.1016/j.ijid.2008.05.576
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Culture Proven Treatment Failures in Patients with Ery-
thema Migrans Treated with Azithromycin, Amoxicillin,
Cefuroxime Axetil, or Doxycycline
F. Strle ∗, E. Ruzic-Sabljic, S. Lotric-Furlan, J. Cimperman,
M. Logar, A. Pikelj-Pecnik, D. Cerar, V. Maraspin
University Medical Centre Ljubljana (Department Of Infec-
tious Diseases), Ljubljana, Slovenia
Background: Azithromycin has been utilized for treat-
ment of patients with solitary erythema migrans for more
than 15 years however the information on its efﬁcacy has
been equivocal. The data have been based nearly exclusively
on clinical ﬁndings; no comparative study on the microbio-
logical assessment of the efﬁcacy has been published.
Methods: Prospectively gained data on adult patients
diagnosed with erythema migrans at Lyme borreliosis Outpa-
tient’s Clinic in Ljubljana, Slovenia, from 1997 to 2003 and
from 2005 to 2007, formed the basis for this presentation.
Patients with Borreliae isolated from the skin lesion prior to
treatment (during last years isolation rate was about 50%)
with azithromycin (500mg b.i.d. for the ﬁrst day, followed
by 500mg o.d. for further 4 days), doxycycline (100mg
b.i.d. for 14 days), amoxicillin (500mg t.i.d. for 14 days),
or cefuroxime axetil (500mg b.i.d. for 14 days), in whom
skin biopsy was repeated at the site of previous procedure
2-3 months later and specimen cultured in the MKP or BSK-II
medium for up to 12 weeks for the presence of Borreliae,
qualiﬁed for this presentation. Persistence of the etiological
agent (i.e. ﬁnding of Borreliae before and 2-3 months after
antibiotic treatment) in skin was interpreted as treatment
failure. Findings for individual antibiotics were compared
using Yate’s corrected Fisher’s test.
Results: Persistence of Borreliae in normal looking skin at
the site of previous erythema migrans was found in 35/1961
(1.8%) patients: in 9/547 (1.6%) treated with azithromycin,
in 7/457 (1.5%) treated with amoxicillin, in 8/444 (1.8%)
treated with doxycycline, and in 11/513 (2.1%) who were
given cefuroxime axetil (unsigniﬁcant differences).
Conclusion: Microbiological assessment of the efﬁcacy of
treatment of early Lyme borreliosis revealed that treatment
failures are rare. No statistically signiﬁcant differences
between azithromycin and compartive drugs were found.
doi:10.1016/j.ijid.2008.05.577
